GGHC
JANX icon

Gilder Gagnon Howe & Co’s Janux Therapeutics JANX Stock Holding History

Gilder Gagnon Howe & Co’s Portfolio JANX Stock Details JANX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-38,255
Closed -$935K – 267
2025
Q3 		$935K Sell
38,255
-7,156
-16% -$174K 0.01% 223
2025
Q2 		$1.05M Sell
45,411
-4,695
-9% -$124K 0.01% 201
2025
Q1 		$1.35M Sell
50,106
-2,273
-4% -$85.7K 0.02% 179
2024
Q4 		$2.8M Buy
52,379
+41,030
+362% +$2.17M 0.03% 174
2024
Q3 		$516K Sell
11,349
-205
-2% -$8.92K 0.01% 230
2024
Q2 		$484K Sell
11,554
-37
-0.3% -$1.74K 0.01% 233
2024
Q1 		$436K Buy
+11,591
New +$252K 0.01% 244

Other funds holding JANX

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PM
Prosight Management Dallas, Texas $580M AUM 29.81% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Gilder Gagnon Howe & Co's JANX Position: Q4 2025 in Review

Gilder Gagnon Howe & Co sold out of Janux Therapeutics (JANX) in Q4 2025, closing a stake of 38,255 shares — an estimated $935K sold.

Gilder Gagnon Howe & Co first reported a position in JANX in Q1 2024 and held it in 7 quarters. The position peaked at $2.8M in Q4 2024. 176 funds tracked by Wall St. Rank hold JANX as of Q4 2025.

  • Gilder Gagnon Howe & Co reported no remaining Janux Therapeutics position as of Q4 2025 after selling out during the quarter.
  • Gilder Gagnon Howe & Co sold 38,255 Janux Therapeutics shares in Q4 2025, an estimated $935K.
  • Gilder Gagnon Howe & Co first reported a position in Janux Therapeutics in Q1 2024 and held it in 7 quarters.
  • Gilder Gagnon Howe & Co's Janux Therapeutics position peaked at $2.8M in Q4 2024.
  • 176 funds tracked by Wall St. Rank held Janux Therapeutics as of Q4 2025.

Based on Gilder Gagnon Howe & Co's 13F filing for Q4 2025, filed 17 Feb 2026.